• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
J Virol. Apr 1993; 67(4): 2370–2375.
PMCID: PMC240401

Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL.

Abstract

Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region. Although only 50% of the cats vaccinated with ALVAC-FL(dl IS) were protected against persistent viremia after oronasal exposure to a homologous FeLV isolate, all cats administered ALVAC-FL resisted the challenge exposure. Significantly, protection was afforded in the absence of detectable FeLV-neutralizing antibodies. These results represent the first effective vaccination of cats against FeLV with a poxvirus-based recombinant vector and have implications that are relevant not only to FeLV vaccine development but also to developing vaccines against other retroviruses, including human immunodeficiency virus.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Baxby D, Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine. 1992;10(1):8–9. [PubMed]
  • Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992 Jun 13;339(8807):1429–1432. [PubMed]
  • Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science. 1985 Oct 25;230(4724):453–455. [PubMed]
  • Clark N, Kushner NN, Barrett CB, Kensil CR, Salsbury D, Cotter S. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection. J Am Vet Med Assoc. 1991 Nov 15;199(10):1433–1443. [PubMed]
  • Dreyfuss G, Adam SA, Choi YD. Physical change in cytoplasmic messenger ribonucleoproteins in cells treated with inhibitors of mRNA transcription. Mol Cell Biol. 1984 Mar;4(3):415–423. [PMC free article] [PubMed]
  • Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science. 1986 Nov 7;234(4777):728–731. [PubMed]
  • Fischinger PJ, Blevins CS, Nomura S. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol. 1974 Jul;14(1):177–179. [PMC free article] [PubMed]
  • Gilbert JH, Pedersen NC, Nunberg JH. Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals. Virus Res. 1987 Feb;7(1):49–67. [PubMed]
  • Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol. 1990 Jun;64(6):2653–2659. [PMC free article] [PubMed]
  • Hoover EA, Perigo NA, Quackenbush SL, Mathiason-DuBard CK, Overbaugh JM, Kloetzer WS, Elder JH, Mullins JI. Protection against feline leukemia virus infection by use of an inactivated virus vaccine. J Am Vet Med Assoc. 1991 Nov 15;199(10):1392–1401. [PubMed]
  • Issel CJ, Horohov DW, Lea DF, Adams WV, Jr, Hagius SD, McManus JM, Allison AC, Montelaro RC. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol. 1992 Jun;66(6):3398–3408. [PMC free article] [PubMed]
  • Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature. 1988 Jan 21;331(6153):280–283. [PubMed]
  • Mandecki W. Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7177–7181. [PMC free article] [PubMed]
  • Miyazawa M, Nishio J, Chesebro B. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol. 1992 Jul;66(7):4497–4507. [PMC free article] [PubMed]
  • Pedersen NC, Johnson L, Birch D, Theilen GH. Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Vet Immunol Immunopathol. 1986 Feb;11(2):123–148. [PubMed]
  • Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol. 1989 Sep;63(9):3829–3836. [PMC free article] [PubMed]
  • Piccini A, Perkus ME, Paoletti E. Vaccinia virus as an expression vector. Methods Enzymol. 1987;153:545–563. [PubMed]
  • Riviere M, Tartaglia J, Perkus ME, Norton EK, Bongermino CM, Lacoste F, Duret C, Desmettre P, Paoletti E. Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants. J Virol. 1992 Jun;66(6):3424–3434. [PMC free article] [PubMed]
  • Stewart MA, Warnock M, Wheeler A, Wilkie N, Mullins JI, Onions DE, Neil JC. Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol. 1986 Jun;58(3):825–834. [PMC free article] [PubMed]
  • Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992 May;188(1):217–232. [PubMed]
  • Taylor J, Edbauer C, Rey-Senelonge A, Bouquet JF, Norton E, Goebel S, Desmettre P, Paoletti E. Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol. 1990 Apr;64(4):1441–1450. [PMC free article] [PubMed]
  • Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P, Paoletti E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine. 1991 Mar;9(3):190–193. [PubMed]
  • Taylor J, Weinberg R, Kawaoka Y, Webster RG, Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine. 1988 Dec;6(6):504–508. [PubMed]
  • Taylor J, Weinberg R, Tartaglia J, Richardson C, Alkhatib G, Briedis D, Appel M, Norton E, Paoletti E. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology. 1992 Mar;187(1):321–328. [PubMed]
  • Wardley RC, Berlinski PJ, Thomsen DR, Meyer AL, Post LE. The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. J Gen Virol. 1992 Jul;73(Pt 7):1811–1818. [PubMed]
  • Yoshinaka Y, Katoh I, Copeland TD, Oroszlan S. Translational readthrough of an amber termination codon during synthesis of feline leukemia virus protease. J Virol. 1985 Sep;55(3):870–873. [PMC free article] [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...